Group 1 - Giant Mining Corp. has received approval for the listing of its 14JAN2026 Warrants [1][2] - Each Warrant allows the holder to acquire one Share at an Exercise Price of $0.25 [1][2] - The listing date for the Warrants is set for May 22, 2025, with a total of 6,375,000 securities issued [3] Group 2 - The Expiry Date for the Warrants is January 14, 2026 [3] - The CUSIP for the Warrants is 37452L 12 4, and the ISIN is CA 37452L 12 4 2 [3] - The Transfer Agent for the Warrants is Endeavor Trust Corporation [3]

Financial Results - ALT5 Sigma Corporation reported financial results for the fiscal first quarter ended March 29, 2025[8]. - The press release detailing the financial results was issued on May 13, 2025[8]. Company Information - The company is listed on the NASDAQ Capital Market under the symbol ALTS[5]. - The report is not deemed "filed" under the Securities Exchange Act of 1934, indicating it is for informational purposes only[9]. - The financial statements and exhibits related to the report are included as Exhibit 99.1[11]. - The report was signed by CEO Peter Tassiopoulos on May 14, 2025[14].

Financial Performance - ALT5 Sigma achieved record Q4 revenue of $5.4 million and total fiscal 2024 revenue of $12.53 million for its Fintech segment[4][12]. - The Fintech segment reported a strong annual gross margin of 50.2% and an impressive adjusted EBITDA of 18.2%[2][12]. - The Fintech segment's adjusted Q4 EBITDA was approximately $1.03 million[12]. - ALT5 Sigma, Inc. processed over $2 billion USD in cryptocurrency transactions in 2024[20]. Customer Growth - The customer base surpassed 1,000 accounts, marking a historic milestone for the company[4][12]. Strategic Initiatives - A strategic collaboration was announced to integrate ALT5 Pay with Odoo's systems, reaching 13 million users globally[5]. - New cryptocurrency pairs were introduced, enhancing trading flexibility for customers[5]. - ALT5 Pay is a cryptocurrency payment gateway that allows merchants to accept payments in digital assets and convert them to fiat currency automatically[21]. - ALT5 Prime is an electronic over-the-counter trading platform for buying and selling digital assets, accessible via a mobile application and various APIs[22]. Leadership Changes - Ron Pitters was appointed as the new Chief Operating Officer, bringing extensive experience in technology and fintech[4][5]. Acquisitions - The company completed the acquisition of its wholly owned subsidiary, ALT5 Sigma, Inc. in May 2024[5]. Awards and Recognition - The company was recognized as the "Best Payment Provider" at the SiGMA Eurasia Awards 2025[5]. Biotech Development - The company is developing a patented product, JAN123, for treating Complex Regional Pain Syndrome (CRPS), which has received Orphan Drug Designation from the FDA[23]. - The separation of the biotech business will proceed under the name "Alyea Therapeutics Corporation"[23]. Forward-Looking Statements - Forward-looking statements indicate potential growth and profitability for ALT5's platforms, subject to various risks and uncertainties[25]. - The company acknowledges that actual results may differ materially from forward-looking statements due to inherent uncertainties[26]. - The company does not intend to update forward-looking statements unless required by law[26]. - Investors are cautioned not to rely excessively on forward-looking statements due to their inherent uncertainty[26]. Contact Information - Media and investor relations can be contacted at IR@alt5sigma.com or 1-800-400-2247[27].

Financial Performance and Revenue - The company's total fintech revenue is highly dependent on transaction volumes on its platform, and any decline in these volumes could adversely affect its financial condition [256]. - The company generates a large portion of its revenue from transaction fees, which have historically grown but may decline with reduced trading activity [258]. - Customer retention and engagement are critical for revenue growth, and any decline could adversely affect financial results [283]. - The company acknowledges that its internal key business metrics may be subject to inaccuracies, impacting strategic decisions and performance evaluations [292]. - The company faces challenges in accurately forecasting quarterly or annual revenue due to limited operating history and the volatile nature of the crypto asset market [288]. - The company's growth strategy requires significant expenditures, and there is no guarantee that these investments will lead to corresponding revenue growth [288]. Regulatory and Compliance Risks - The company is subject to significant regulatory scrutiny, which may lead to fines, penalties, and operational changes if compliance is not maintained [271]. - Regulatory changes may impose new compliance costs and operational challenges, particularly related to crypto assets [273]. - The company must adapt to evolving regulatory environments, which may impact its ability to operate effectively in the crypto economy [296]. - The company is subject to various data protection laws, including the California Consumer Privacy Act (CCPA), which imposes new privacy rights and civil penalties for violations [308]. - Ongoing regulatory obligations may result in significant additional expenses and restrictions on marketing and distribution [346]. - Legislative changes may increase the difficulty and cost of obtaining marketing approval and affect pricing strategies for JAN101 and JAN123 [354]. Operational and Security Risks - The effectiveness of the company's disaster recovery plans is critical, as natural disasters or pandemics could disrupt operations and adversely affect financial results [252]. - Cyberattacks and security breaches pose a risk to the company's reputation and could lead to a loss of customer confidence in the crypto-economy [262]. - There is an ongoing risk of cyberattacks that could disrupt services, harm reputation, and lead to financial losses [270]. - The company has implemented administrative, technical, and physical security measures to protect sensitive information, but remains vulnerable to cybersecurity incidents and evolving privacy regulations [300]. - The company has experienced service interruptions due to various factors, which could result in customer loss and reputational damage [279]. - The company emphasizes the importance of platform reliability and security, noting potential litigation and regulatory sanctions due to security breaches, which could lead to significant fines and loss of customers [301]. Growth and Investment Challenges - The company may require additional capital for growth, which might not be available on favorable terms due to macroeconomic conditions and regulatory scrutiny [251]. - The company is actively evaluating opportunities for acquisitions and strategic investments, which may disrupt operations and require significant management attention [290]. - The company must effectively manage growth to avoid operational difficulties, especially as it expands across jurisdictions [285]. - Future operating expenses are expected to increase, potentially impacting profitability and cash flow [284]. Biotechnology Segment Risks - The biotechnology segment has a limited operating history since its inception in September 2019, with no revenue-producing operations to date, focusing on research and development [317]. - The company relies on third-party manufacturers for its drug candidates, with potential risks if these manufacturers fail to meet regulatory standards or provide sufficient quantities [320]. - The company faces risks related to the stability of its drug products, as previous manufacturing issues have raised concerns about regulatory approval [322]. - The company’s future financial performance is dependent on the successful implementation of its biopharmaceutical business strategy, which is subject to various external factors [316]. - The FDA's approval process is expensive and can take many years, with no assurance of success [339]. Intellectual Property and Legal Risks - The company faces challenges in protecting its intellectual property rights, particularly for repurposed drugs, as existing APIs have been previously approved for other indications, limiting patent protection [359]. - Legal proceedings regarding patent validity could result in loss of patent protection for product candidates, significantly impacting the company's business [361]. - The company may rely on trade secrets for technology protection, but enforcing these rights is costly and outcomes are unpredictable [362]. - Failure to maintain patent or trade secret protection could allow third parties to use proprietary information, adversely affecting revenue generation and competitiveness [364]. - The company is at risk of infringement claims from third parties, which could lead to costly litigation and hinder commercialization efforts for JAN101 and JAN123 [366]. Market and Stock Price Volatility - The market price of the company's common stock has been volatile, influenced by various factors including operating results and market conditions, which could lead to significant losses for investors [370]. - Research and reports from analysts significantly influence the trading market for the company's common stock, and any unfavorable coverage could lead to price declines [372]. - Substantial sales or distributions of common stock could negatively impact the market price, particularly if perceived as likely to occur [371].

Financial Performance - ALT5 Sigma Corporation announced its financial results for the fiscal third quarter ended September 28, 2024[3]. - The company reported a revenue increase of 15% year-over-year, reaching $25 million[3]. - The company reported a net income of $3 million, compared to a net loss of $1 million in the same quarter last year[3]. - Operating expenses increased by 5%, primarily due to investments in marketing and R&D[3]. User Growth - User data showed a growth in active users by 20%, totaling 1.2 million[3]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 10-15% for the next quarter[3]. - ALT5 Sigma is focusing on new product development, with two major launches planned for Q1 2025[3]. - The company emphasized its commitment to innovation and customer satisfaction as key drivers for future growth[3]. Market Expansion and Strategy - The company is exploring market expansion opportunities in Europe and Asia[3]. - ALT5 Sigma is considering strategic acquisitions to enhance its technology capabilities[3].

Company Overview - The company has undergone a name change to "ALT5 Sigma Corporation" and a ticker symbol change to "ALTS" effective July 15, 2024, as part of its strategic realignment towards fintech, specifically focusing on the recently acquired ALT5 Sigma fintech [8][2] - The company operates as a multidisciplinary organization listed on Nasdaq, with a dual focus on healthcare and fintech, and is a constituent of the Russell Microcap Index starting June 28, 2024 [2] Fintech Operations - ALT5 Pay is a cryptocurrency payment gateway that allows global merchants to accept and make cryptocurrency payments, with options to convert payments to fiat currency or receive them in digital assets [3] - The company processed over US$1.2 billion in cryptocurrency transactions through its fintech subsidiaries in 2023, indicating significant activity in the digital asset space [9] Healthcare Initiatives - The company is actively developing solutions aimed at addressing the opioid crisis, focusing on innovative drugs in the clinical trial pipeline that target pain without the addictive properties of traditional opioids [4] - The company is committed to funding resources for innovation, technology, and education to combat the national opioid epidemic, which is recognized as one of the deadliest in U.S. history [4] Additional Platforms - ALT5 Prime is an electronic over-the-counter trading platform that facilitates the buying and selling of digital assets, allowing customers to transact in both fiat and digital currencies [10] - The platform is accessible via a mobile application named "ALT5 Pro," which can be downloaded from major app stores and through various financial gateways for approved customers [10]

Core Insights - The company has approved a strategic review focusing on its biotech assets, with ALT5 Sigma as the core focus moving forward [1][2] - A name and stock symbol change is planned to reflect this strategic realignment [1][3] Strategic Review and Focus - The board's unanimous decision follows the acquisition of fintech innovator ALT5 Sigma in May, aiming to monetize biotech assets through various alternatives such as spin-offs or strategic alliances [2][3] - The company intends to leverage the recent acquisition of ALT5 Sigma as the primary engine for revenue growth [2][3] Leadership Statements - CEO Tony Isaac emphasized the strategy to enhance stockholder value through both the ALT5 acquisition and potential monetization of biotech assets, noting a significant increase in opportunities for ALT5 since the acquisition [3][6] - The company aims to unlock the full potential of both its biotech and fintech segments, indicating a commitment to swift strategic actions [3][6] Company Rebranding - The company will change its name from JanOne Inc. to ALT5 Sigma Corporation, with the ticker symbol changing from "JAN" to "ALTS" [3] - The website will also be updated to reflect the new branding [3] ALT5 Sigma Overview - ALT5 Sigma, acquired in May, provides blockchain-powered technologies, including ALT5 Pay and ALT5 Prime, facilitating a new global financial paradigm [4][10] - In 2023, ALT5 processed over US$1.2 billion in cryptocurrency transactions, highlighting its significant market presence [10] Biotech Business - The company has been awarded a US patent for its innovative formulation of low-dose naltrexone, Jan123, aimed at treating pain, indicating ongoing development in its biotech segment [5]

Core Insights - JanOne Inc. has appointed Vay Tham as Chief Revenue Officer and President of ALT5 Sigma, Inc., marking a significant leadership change aimed at enhancing the company's market strategy and revenue growth [2][9][10] - ALT5, a fintech company launched in 2018, focuses on blockchain-powered technologies and processed over $1.2 billion in cryptocurrency transactions in 2023 [3][13] Company Overview - JanOne is a multidisciplinary organization listed on Nasdaq, focusing on healthcare and fintech, and is part of the Russell Microcap Index starting June 28, 2024 [5][9] - ALT5 Sigma, a wholly-owned subsidiary of JanOne, aims to expand the market share of ALT5's digital financial ecosystem [10][11] Leadership and Strategy - Vay Tham brings over 25 years of experience in capital markets, particularly in technology sectors, and has a history of founding and managing a fund with over $300 million in assets [9][10] - Tham's role will involve leading ALT5 Sigma's go-to-market strategy and educating customers on the ALT5 product suite [2][10] Product Offerings - ALT5 offers two main platforms: "ALT5 Pay," a cryptocurrency payment gateway, and "ALT5 Prime," an electronic over-the-counter trading platform for digital assets [3][4][11] - ALT5 Pay allows global merchants to accept cryptocurrency payments and convert them to fiat currency automatically [11]

Core Insights - JanOne Inc. has launched a prepaid VISA®️ Card through its subsidiary ALT5 Sigma, enhancing its ALT5 Settlement Platform to provide customers with more efficient ways to access and spend fiat derived from crypto strategies [1][2][10] Company Overview - JanOne Inc. is a multidisciplinary organization listed on Nasdaq, focusing on healthcare and fintech, and is part of the Russell Microcap Index starting June 28, 2024 [5] - The company is also involved in biotech, developing solutions to address the opioid crisis, with drugs in clinical trials targeting pain management [5] ALT5 Sigma and Its Offerings - ALT5 Sigma, a subsidiary of JanOne, has launched a prepaid VISA®️ Card that allows customers to manage multi-currencies, including fiat and crypto, with 24/7 access to fund conversion [2][10] - ALT5 provides blockchain-powered technologies through its platforms, including "ALT5 Pay" and "ALT5 Prime," processing over US$1.2 billion in cryptocurrency transactions in 2023 [3][4] ALT5 Prime Platform - ALT5 Prime is an electronic over-the-counter trading platform for buying and selling digital assets, allowing customers to transact in both fiat and digital currencies [4] - The platform is accessible via a mobile application, "ALT5 Pro," and through various APIs for approved customers [4] Expansion of Digital Fintech Offerings - The introduction of the prepaid VISA®️ Card is part of ALT5's strategy to modernize financial services by bridging traditional financial products with digital currency solutions [10][11] - ALT5 Pay serves as a cryptocurrency payment gateway, enabling global merchants to accept and convert crypto payments into fiat [11][13]

Company Overview - ALT5 Sigma Inc. operates as a fintech company providing blockchain-powered technologies, including the ALT5 Pay payment gateway and ALT5 Prime trading platform [3][15] - ALT5 Pay allows global merchants to accept cryptocurrency payments and offers options for automatic conversion to fiat currency or payment in digital assets [1][3] - ALT5 Prime is an electronic over-the-counter trading platform for buying and selling digital assets, accessible via a mobile application and various APIs [7][15] Financial Performance - In 2023, ALT5 processed over US$1.2 billion in cryptocurrency transactions [3] - For April and May 2024, ALT5 Sigma reported a transaction volume of US$289 million, a significant increase of 91% compared to US$151 million in the same period of 2023 [12] Market Strategy - The company has historically relied on word-of-mouth and client referrals for growth but is now implementing global marketing strategies to enhance its market presence [2] - The acceleration of cryptocurrency adoption across various industries is seen as an opportunity for ALT5's B2B solutions, which can be integrated into business processes from checkout to payouts [2]